Literature DB >> 2393265

Pharmacokinetics and tissue penetration of ceftibuten.

R Wise1, K Nye, P O'Neill, M Wostenholme, J M Andrews.   

Abstract

The pharmacokinetics of the cephalosporin ceftibuten were determined after the fifth and final dose of 200 mg given every 12 h. Concentrations in plasma and cantharidin-induced inflammatory fluid were determined by a microbiological assay. Samples for three volunteers were assayed by a high-performance liquid chromatographic procedure to determine levels for both cis and trans ceftibuten. The mean peak level of ceftibuten in serum was 10.9 micrograms/ml at a mean time of 1.8 h after administration, and the mean elimination half-life from plasma was 2.5 h. Penetration into the inflammatory fluid was good, the mean peak level being 9.2 micrograms/ml at a mean time of 3.7 h. The mean percent penetration into the inflammatory fluid was 113.4%. High-performance liquid chromatography analysis showed that the mean peak level of the trans isomer was 5.7% that of the cis isomer. This study suggests that twice-daily doses of ceftibuten should be sufficient to treat urinary or systemic infections caused by susceptible pathogens.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2393265      PMCID: PMC171757          DOI: 10.1128/AAC.34.6.1053

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

2.  Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

3.  PHARM--an interactive graphic program for individual and population pharmacokinetic parameter estimation.

Authors:  R Gomeni
Journal:  Comput Biol Med       Date:  1984       Impact factor: 4.589

4.  The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin/clavulanic acid.

Authors:  R Wise; S A Bennett; J Dent
Journal:  J Antimicrob Chemother       Date:  1984-06       Impact factor: 5.790

5.  The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.

Authors:  R Wise; A P Gillett; B Cadge; S R Durham; S Baker
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

6.  Cefixime, in-vitro activity, pharmacokinetics and tissue penetration.

Authors:  J W Stone; G Linong; J M Andrews; R Wise
Journal:  J Antimicrob Chemother       Date:  1989-02       Impact factor: 5.790

  6 in total
  10 in total

Review 1.  Comparative pharmacokinetics of the new oral cephalosporins.

Authors:  H Lode; M Fassbender; T Schaberg; K Borner; P Koeppe
Journal:  Drugs       Date:  1994       Impact factor: 9.546

2.  Penetration of ceftibuten into middle ear fluid.

Authors:  C Lin; P Kumari; R J Perrotta; B E Reidenberg
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  Treatment of acute uncomplicated urinary tract infection with ceftibuten.

Authors:  G E Stein; S Christensen; N Mummaw
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

4.  Ceftibuten in paediatrics.

Authors:  R D Colucci; M Elliott; M B Affrime; N Zampaglione
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

5.  Pharmacokinetics of cefetamet in plasma and skin blister fluid.

Authors:  W Zimmerli; S Sansano; B Wittke
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

Review 7.  Ceftibuten pharmacokinetics and pharmacodynamics. Focus on paediatric use.

Authors:  G L Kearns; R A Young
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

8.  Pharmacokinetics and pharmacodynamics of newer oral cephalosporins: implications for treatment of community-acquired lower respiratory tract infections.

Authors:  M Cazzola; M G Matera; C F Donner
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

9.  Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections.

Authors:  C O Onyeji; D P Nicolau; C H Nightingale; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

Review 10.  Ceftibuten. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.